Products
Brivekimig Biosimilar Trispecific Single-Domain Antibody (OX40L × TNF-α × Albumin) for Research
Cat No.: GMP-Bios-INN-1112
Anti-TNFSF4/CD134/CD252/OX40L therapeutic antibody (Pre-made Brivekimig biosimilar,Trispecific Single Domains (VH-VH-VH'-VH''-VH')) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Brivekimig (development code SAR 442970) is a trispecific antibody targeting OX40 ligand (TNFSF4), TNF and albumin. It is developed by Sanofi for focal segmental glomerulosclerosis, hidradenitis suppurativa. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1112-1mg | 1mg | |
| GMP-Bios-INN-1112-10mg | 10mg | |
| GMP-Bios-INN-1112-100mg | 100mg | |
| GMP-Bios-INN-1112-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Brivekimig biosimilar, Trispecific Single Domains (VH-VH-VH'-VH''-VH'), Anti-TNFSF4/CD134/CD252/OX40L;TNF/TNFA;ALB Antibody: Anti-OX40L/TNFSF4/CD252/OX40 therapeutic antibody |
| INN Name | Brivekimig |
| Target | TNFSF4/CD134/CD252/OX40L;TNF/TNFA;ALB |
| Format | Trispecific Single Domains (VH-VH-VH'-VH''-VH'); Bispecific entry |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | na |
| VD LC | na;na |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | Sanofi |
| Conditions Approved | na |
| Conditions Active | Focal segmental glomerulosclerosis;Hidradenitis suppurativa |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
